The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1525
July 17, 2017
View Complete Issue         Table of Contents 2017 
Drugs for Helicobacter pylori Infection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
July 17, 2017 (Issue: 1525)
Revised 3/7/18: Information warning about an increased risk of cardiac events and death with clarithromycin has been added.

About 50% of the world’s population is infected with Helicobacter pylori. These gastric bacteria can cause chronic inflammation and have been associated with development of gastritis, peptic ulcer disease, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.1 Eradication of H. pylori can promote gastric healing, prevent recurrence of duodenal and gastric ulcers, and reduce the incidence of gastric cancer.2,3 Guidelines for treatment of H. pylori infection were updated recently.4-6

NONINVASIVE TESTING — Urea Breath Tests – A urea breath test (BreathTek; BreathID; PYtest) can be used for office-based diagnosis of H. pylori infection. The patient ingests a urea solution or urea-containing capsule labeled with a carbon ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Helicobacter pylori Infection
Article code: 1525a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian